Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Ralph Audehm & Prof Simone Strasser

A/Prof Ralph Audehm & Prof Simone Strasser

Abnormal LFTs – Practical Cases Expert Q&A

Prof Andrew Sindone AM

Prof Andrew Sindone AM

MRAs for Heart Failure Update - New Developments

Prof David Price

Prof David Price

COPD Exacerbation – Inhaled steroids vs Pneumonia Risks – It's Not Black and White

Angela Newbound

Angela Newbound

Practical Strategies to Increase Vaccination Rates This Flu Season

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022